

SPECIALTY QUANTITY LIMIT PROGRAM

SIGNIFOR (pasireotide)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Signifor (pasireotide) subcutaneous injection 0.3 mg/mL	60 per 30 days	Recommended initial dosage: 0.6 mg or 0.9 mg injection twice a day Recommended dosage range is 0.3 mg to 0.9 mg twice a day based on response, tolerability, and adverse effects.
Signifor (pasireotide) subcutaneous injection 0.6 mg/mL	60 per 30 days	
Signifor (pasireotide) subcutaneous injection 0.9 mg/mL	60 per 30 days	

III. REFERENCES

1. Signifor [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2019.